Showing results (161-170 of 176) with videos related to
Sort By:
Pageof 18
Therapeutic Advances in Medical Oncology|September 2, 2022
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancerElyssa Denault, Erika Nakajima, Vivek Naranbhai, et al.Journal of the American College of Surgeons|May 17, 2023
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical TrialAnna Weiss, Tianyu Li, Neelam V Desai, et al.JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.Journal for Immunotherapy of Cancer|April 3, 2026
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancerBogang Wu, Win Thant, Elena Bitman, et al.JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.Microbiology Resource Announcements|October 26, 2022
Complete Genome Sequences of Microbacterium paraoxydans Phages Cassita and FransoyerBrynn R Bauer, Madelyn G Brookins, Spencer Fobbe, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter ExperienceSeth A Wander, Hyo S Han, Mark L Zangardi, et al.Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.The Lancet. Oncology|April 30, 2026
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trialSeth A Wander, Maxwell R Lloyd, Jennifer C Keenan, et al.Cancer Discovery|November 2, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA MutationsAndreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, et al.Pageof 18